MTOR and neoplasm: Furthermore, CWR22 xenografts treated with a combination of PI3K/mTOR inhibitor and either Riluzole (blocking agent for glutamate release) or lapatinib showed significant reduction in tumor volume after a 2-week treatment, when compared with their single-agent controls (Fig. 6C; Supplementary Fig. S5C).